Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT06200467
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT06194032
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06162286
- Locations
- 🇨🇳
The Third Hospital of Changsha/Respiratory and Critical Care Medicine Department, Changsha, China
🇨🇳Kunming First People's Hospital/Respiratory Medicine, Kunming, China
🇨🇳Shanghai Pulmonary Hospital/Respiratory and Critical Care Medicine Department, Shanghai, China
A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 46
- Registration Number
- NCT06107036
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06070597
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Microbiome Effect of Omadacycline on Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- University of Houston
- Target Recruit Count
- 32
- Registration Number
- NCT06030219
- Locations
- 🇺🇸
University of Houston, Houston, Texas, United States
A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- AN2 Therapeutics, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05995444
- Locations
- 🇺🇸
423001, Tempe, Arizona, United States
A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 58
- Registration Number
- NCT05988034
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Altavant Sciences GmbH
- Target Recruit Count
- 27
- Registration Number
- NCT05933447
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.